Eurofins Discovery offers one the drug discovery industry’s largest portfolios of human preclinical safety assessments, ranging from simple cytotoxicity assays in cell lines to prediction of adverse clinical outcomes in primary cell, translationally-relevant disease models.
Hand-in-hand with these assays and services is our team expertise across multiple disciplines — providing advice and collaboration to positively influence the safety of preclinical candidates. From chemistry and high-throughput screening to ADME-toxicology, safety pharmacology, and translational biology, we can help you discover, de-risk, and prioritize for efficacy and safety.
Key Stages for Safety Evaluation
Figure. Schematic of drug discovery phases amenable to safety screening & profiling. Eurofins Discovery assays provide clients options to identify and select scaffolds with desirable pharmacokinetic properties, to accelerate candidate selection through triage, to predict adverse outcomes and to mitigate risk.
We are ready to help you bring forward safer preclinical candidates with early hazard identification and off-target mitigation, strategies to design out potential liabilities during SAR (Structure-Activity Relationship) modeling, and services to improve understanding of toxicity signatures and potential adverse outcomes.
Highlights of our functional assays and services for safety and toxicity assessment of small molecules and biologics include:
- BioMAP® Toxicity Signature Analysis – Reveal safety concerns or potential adverse outcomes based on the presence of established biomarker profiles associated with increased risk of adverse outcomes
- BioMAP Early Screening Services – Quickly obtain disease-focused data to prioritize, triage, and classify large numbers of test agents based on efficacy and safety-related readouts
- Biomarker Services – Obtain safety insights with custom counter screens and Cytokine Storm Assay
- In vivo safety models from our partner lab, Pharmacology Discovery Services
